Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 70.35
-1.60 (-2.22%)
Feb 13, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Market Cap
Shanghai Henlius Biotech has a market cap or net worth of 39.1 billion as of February 12, 2026. Its market cap has increased by 320.76% in one year.
Market Cap
39.10B
Enterprise Value
42.06B
Revenue
6.35B
Ranking
n/a
PE Ratio
43.29
Stock Price
70.35
Market Cap Chart
Since September 25, 2019, Shanghai Henlius Biotech's market cap has increased from 26.66B to 39.10B, an increase of 46.68%. That is a compound annual growth rate of 6.18%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 12, 2026 | 39.10B | 26.12% |
| Dec 31, 2025 | 31.01B | 140.72% |
| Dec 31, 2024 | 12.88B | 70.50% |
| Dec 29, 2023 | 7.55B | 8.59% |
| Dec 30, 2022 | 6.96B | -41.95% |
| Dec 31, 2021 | 11.98B | -53.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| 3SBio | 60.24B |
| RemeGen | 58.52B |
| Shanghai Junshi Biosciences | 35.94B |
| Biocytogen Pharmaceuticals (Beijing) | 34.89B |
| Duality Biotherapeutics | 30.54B |
| TransThera Sciences (Nanjing) | 28.41B |
| Genscript Biotech | 27.94B |
| PegBio | 26.40B |